KAKEN PHARMACEUTIAL CO., LTD. Logo

KAKEN PHARMACEUTIAL CO., LTD.

R&D pharma firm creating drugs & devices for orthopedics, dermatology, and surgery globally.

4521 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
文京区本駒込二丁目28番8号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kaken Pharmaceutical Co., Ltd. is an R&D-driven pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription drugs, medical devices, and agrochemicals. The company focuses on creating innovative treatments, particularly in the fields of orthopedics, dermatology, and surgery. Its main products include Artz, an anti-osteoarthritis agent, and Clenafin, a treatment for onychomycosis. Kaken Pharmaceutical also has operations in animal health and real estate. With a corporate philosophy centered on improving patients' quality of life, the company distributes its products both in Japan and internationally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-09 07:12
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.2 KB
2025-08-06 08:52
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.2 KB
2025-07-09 08:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2025-07-01 02:34
Regulatory News Service
臨時報告書
Japanese 28.2 KB
2025-06-26 03:41
Governance Information
内部統制報告書-第105期(2024/04/01-2025/03/31)
Japanese 24.6 KB
2025-06-26 03:39
Registration Form
確認書
Japanese 8.7 KB
2025-06-26 03:38
Annual Report
有価証券報告書-第105期(2024/04/01-2025/03/31)
Japanese 1.8 MB
2025-06-11 06:41
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.7 KB
2025-05-30 08:42
Share Issue/Capital Change
臨時報告書
Japanese 84.4 KB
2025-05-14 05:01
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.3 KB
2025-04-10 04:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.5 KB
2025-03-12 02:56
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.1 KB
2024-12-26 07:35
Registration Form
有価証券届出書(参照方式)
Japanese 82.4 KB
2024-11-13 05:25
Interim Report
確認書
Japanese 8.7 KB
2024-11-13 05:24
Interim Report
半期報告書-第105期(2024/04/01-2025/03/31)
Japanese 243.3 KB

Automate Your Workflow. Get a real-time feed of all KAKEN PHARMACEUTIAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for KAKEN PHARMACEUTIAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.